The personalized cell therapy market involves the modification of human cells for providing customized treatment to patients suffering from cancer and other chronic diseases. These therapies offer several advantages like enhanced safety and efficacy profiles. Cell therapies enable doctors to reprogram a patient’s own cells to cure diseases by rebalancing the immune system.

The global personalized cell therapy market is estimated to be valued at US$ 6.41 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period from 2024 to 2031.

Key players operating in the personalized cell therapy market are Continental AG, Valeo, Robert Bosch, Denso Corporation, Magna International, Ficosa, ZF Friedrichshafen, Gentex, Aptiv, Renesas Electronics. These players are focusing on new product launches and investments in research and development activities to strengthen their market positions.

The demand for Personalized Cell Therapy Market Demand is growing rapidly owing to the rising cancer prevalence worldwide. According to global cancer statistics, cancer burden has risen to 19.3 million new cases and 10 million cancer deaths in 2020. Cell therapies offer patients improved survival and regression of tumors with manageable side-effects. Growing geriatric population vulnerable to chronic diseases is also driving the adoption of personalized medicine.

Global expansion of key players in the personalized cell therapy market through acquisitions and partnerships allow greater access to innovative treatment options in developing regions. For instance, in 2020, Bayer AG acquired cell therapy company BlueRock Therapeutics to enhance its position in the high-growth area of engineered cell therapies for diseases with high unmet medical needs. More biopsy and diagnostic centers are also being set up worldwide to facilitate cell collection & processing.

Adoption of artificial intelligence (AI) and big data analytics enable precision in personalized cell therapies. AI helps identify patterns in genomic information to develop better personalized treatments. It also assists in predicting immunotherapy responses and identifying patients likely to benefit most. Integration of AI with cell therapy manufacturing is a major trend allowing for personalized, quality medicine at lower costs.

Porter’s Analysis

Threat of new entrants: High capital requirements and regulatory hurdles pose significant barriers for new entrants.

Bargaining power of buyers: Individual customers have low bargaining power due to highly specialized nature of personalized cell therapy products.

Bargaining power of suppliers: Suppliers of raw materials and reagents have moderate bargaining power due to limited availability of specialized cell lines and reagents from biological sources.

Threat of new substitutes: No close substitutes presently exist for personalized cell therapy.

Competitive rivalry: Intense competition among existing players to develop advanced therapies and gain first-mover advantage.

Geographical regions with highest Personalized Cell Therapy Market concentration currently include North America and Europe owing to advanced healthcare infrastructure and high patient acceptability for novel therapies. However, Asia Pacific region is expected to witness fastest growth during forecast period due to increasing investments by governments and private players towards strengthening regional capabilities in cell and gene therapy research.

Geographical regions with highest market concentration currently include North America and Europe owing to advanced healthcare infrastructure and high patient acceptability for novel therapies. However, Asia Pacific region is expected to witness fastest growth during forecast period due to increasing investments by governments and private players towards strengthening regional capabilities in cell and gene therapy research.

*Note:
1.  Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it